The Star Tribune published a special report on Medtronic's Infuse studies on April 10, examining the FDA studies and lawsuits against the company, but ending on CEO Omar Ishrak's plans to expand the marketshare for biografts using Infuse. On ... Becker's Spine Review, 3 weeks ago
How Medtronic Misplaced 1000 Negative Infuse Reports - QMED, 3 weeks ago
A popular—and frequently litigated—implantable medical device has come under congressional scrutiny after allegations of data suppression arose. Medtronic manufacturers and markets the Infuse® Bone Graft/LT-Cage® Lumbar Tapered Fusion Device ...Wolters Kluwer Law & Business, 2 weeks ago
on your WebpageAdd Widget >Get your members hooked!